Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Emicizumab

Shire teams up with Microsoft and EURORDIS for rare disease project

Will work to accelerate the time to diagnosis for children

Roche Basel Switzerland

Roche to buy cancer data firm Flatiron for $1.9bn

Data provides a wealth of RWE opportunities

Roche Basel Switzerland

NICE backs Roche’s Gazyvaro after initial rejection

An undisclosed discount swayed the cost-effectiveness body

- PMLiVE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Boehringer Ingelheim’s Ofev subject to same conditions

- PMLiVE

Roche unveils data for Tecentriq/Avastin combo in kidney cancer

Patients on the combo had a lengthier PFS than those on Pfizer’s Sutent

Roche Basel Switzerland

Roche faces biosimilar blitz in 2018

Analysts predict copycat competitors will slow the Swiss group’s revenue growth

Roche Basel Switzerland

Roche’s autism drug scores FDA breakthrough status

Balovaptan could become the first drug to treat autism spectrum disorder

Roche Basel Switzerland

Roche wins CHMP backing for Hemlibra

Haemophilia A treatment on course for European approval

- PMLiVE

Shire says all its studies will publish in open access journals

The Irish biotech says its focus on rare diseases was a key factor behind the decision

Shire wins FDA approval for haemophilia dosing software

The web-based myPKFiT supports the pharma firm's Advate treatment

- PMLiVE

Shire claims EU approval for haemophilia A drug Adynovi

The drug will battle Bayer’s Kovaltry and Sobi's Elocta in a bid to capture market share

Roche Basel Switzerland

Roche’s Ocrevus is first primary progressive MS drug in EU

Analysts predict the drug could be a $3bn product by 2021

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links